"Sanofi and Teva report new outcomes from Phase IIb trial of duvakitug" was originally created and published by Clinical ...

"Sanofi and Teva’s duvakitug meets primary endpoints in Phase IIb trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has ...

On December 17, Teva Pharmaceutical Industries Limited reported that duvakitug had shown stunning results in a phase 2b study for the treatment of Crohn's disease and ulcerative colitis.

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

In ulcerative colitis, duvakitug led to clinical remission in ... Also Read: Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As ...

Teva outlines ... LAI, duvakitug, DARI, and emrusolmin. AUSTEDO: Expected to exceed $2.5 billion in sales by 2027 and exceed $3 billion by 2030. AJOVY: A globally established brand with presence ...

After Phase 2 duvakitug data surpassed ... UBS believes Teva is still an under-owned name among Long-only, which UBS expects can change in 2025 as brand transition accelerates and the company ...

This includes 16% sales growth in the U.S., totalling $1 billion, as well as 8% growth in Europe, totalling $970 million As for brand name products ... Of note, Teva said it expects results of ...

The investment firm's decision is buoyed by the potential of Teva's drug candidate duvakitug ... the announcement by Evernorth to exclude the brand Humira from its Express Scripts commercial ...